TXA inhibits plasminogen activation and/or PA in vitro and ex vivo. (A) Mouse normal pooled plasma was diluted 1:6 in HEPES buffer with TXA (concentrations indicated in the legend) and then clotted in the presence of tissue factor, phospholipids, recombinant tissue plasminogen activator, and CaCl2. Fluorescence was monitored over time. Representative curves from 3 replicates are shown. (B-G) Saline or TXA (600 mg/kg) was injected intraperitoneally into wild-type mice. Blood was collected from the inferior vena cava into 3.2% sodium citrate (10% vol/vol, final) and used to prepare plasma for PA measurements. Representative curves of mice treated with (B) saline or (C) TXA for each time point. (D-G) Parameters: (D) lag time, (E) time to peak, (F) velocity, and (G) peak. Saline and TXA treatments are indicated in black and red, respectively. Dots and error bars show mean ± standard error of the mean, N = 4 to 9 individual mice per time point. Groups were compared by ordinary 1-way analysis of variance with the Šidák or the Holm-Šidák multiple comparisons test; ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001 for comparisons at each time point. TtPeak, time to peak.
